{'output': [['Perrigo Company plc', 'ORG', 'Announce', 'tentative approval', 'EVENT'], ['Perrigo Company plc', 'ORG', 'Settle', 'litigation', 'EVENT', 'Bausch & Lomb Inc.', 'ORG'], ['Prolensa ® (bromfenac ophthalmic solution) 0.07%', 'PRODUCT', 'Indicate', 'postoperative inflammation and reduction of ocular pain', 'EVENT', 'Cataract surgery', 'EVENT'], ['Perrigo Company plc', 'ORG', 'Operate_In', 'Rx Pharmaceuticals', 'SECTOR'], ['Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski', 'PERSON', 'State', 'tentative approval illustrates the continued dedication of our R&D and regulatory teams as they work to advance our new product pipeline to deliver Quality Affordable Healthcare Products ® to patients around the world.', 'EVENT']]}